Equities Analysts Offer Predictions for CNTA FY2029 Earnings

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) – Analysts at Leerink Partnrs dropped their FY2029 EPS estimates for Centessa Pharmaceuticals in a research report issued on Wednesday, November 5th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of $0.74 per share for the year, down from their previous forecast of $0.77. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share.

A number of other equities analysts also recently issued reports on the stock. Guggenheim reiterated a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Lifesci Capital raised shares of Centessa Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, September 3rd. Truist Financial set a $30.00 price target on Centessa Pharmaceuticals in a research note on Wednesday. Stephens initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, October 28th. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, Oppenheimer began coverage on Centessa Pharmaceuticals in a research note on Friday, August 29th. They set an “outperform” rating and a $40.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.67.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock traded down $0.91 during trading on Friday, reaching $21.92. The company’s stock had a trading volume of 703,940 shares, compared to its average volume of 1,052,457. The business has a 50 day moving average price of $22.19 and a 200-day moving average price of $17.03. The company has a market capitalization of $2.94 billion, a P/E ratio of -11.97 and a beta of 1.56. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32. Centessa Pharmaceuticals has a 12-month low of $9.60 and a 12-month high of $25.42.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02).

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new position in shares of Centessa Pharmaceuticals in the third quarter worth about $455,000. Federated Hermes Inc. acquired a new position in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $42,429,000. Campbell & CO Investment Adviser LLC boosted its stake in shares of Centessa Pharmaceuticals by 55.5% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 25,845 shares of the company’s stock valued at $627,000 after buying an additional 9,226 shares during the last quarter. SG Americas Securities LLC acquired a new position in Centessa Pharmaceuticals during the 3rd quarter worth $572,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Centessa Pharmaceuticals by 4.8% in the second quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock worth $252,000 after purchasing an additional 870 shares in the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, insider Mario Alberto Accardi sold 8,000 shares of the stock in a transaction on Monday, October 27th. The stock was sold at an average price of $25.00, for a total value of $200,000.00. Following the completion of the sale, the insider directly owned 194,394 shares in the company, valued at approximately $4,859,850. This represents a 3.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Tia L. Bush sold 35,000 shares of the business’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $24.00, for a total value of $840,000.00. Following the transaction, the chief technology officer owned 121,503 shares in the company, valued at approximately $2,916,072. This represents a 22.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 145,964 shares of company stock valued at $3,169,861. Company insiders own 7.09% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.